Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-28T02:05:59.087Z Has data issue: false hasContentIssue false
  • English
  • Français

Common haematological problems in the elderly

Published online by Cambridge University Press:  17 November 2008

JT Reilly
JT Reilly*
Affiliation:
Northern General Hospital, Sheffield, UK
*
JT Reilly, Consultant Haematologist, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Clinical geriatrics
Information
Reviews in Clinical Gerontology , Volume 3 , Issue 4 , November 1993 , pp. 335 - 346
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1Kruger, A.The limits of normality in elderly patients. Clinics Haematol 1987; 1: 271–89.Google ScholarPubMed
2Carpenter, MA, Kendall, RG, O'Brien, AEet al. Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol 1992; 49: 119–21.CrossRefGoogle ScholarPubMed
3Makinodan, T, Kay, MMB. Age influence on the immune system. In: Kunkel, H, Dixon, H eds. Advances in immunology, volume 29. New York: Academic Press, 1980: 289–330.Google Scholar
4Jacobs, A.Genetic lesions in preleukaemia. Leukaemia 1991; 5: 277–82.Google Scholar
5Martineau, M, Potter, AM, Watemore, AE, Secker-Walker, LM. Loss of the Y chromosome from normal and neoplastic bone marrows. London: International Society of Haematology, 24th meeting, 1992: 414.Google Scholar
6Means, RT, Krantz, SB.Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood 1992; 80: 1639–47.CrossRefGoogle Scholar
7Biregegard, G, Gudbjronsson, B, Hallgren, R, Wide, L.Anaemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin. Contrib Nephrol 1991; 88: 295–303.Google Scholar
8Ludwig, H, Fritz, E, Kotzmann, H, Hocker, P, Gisslinger, H, Barnas, U.Erythropoietin treatment of anaemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693–99.CrossRefGoogle ScholarPubMed
9Steiner, RW, Coggins, C, Carvalho, ACA.Bleeding time in uraemia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107–17.Google Scholar
10Eschbach, JW, Kelly, MR, Haley, NR, Abels, RI, Adamson, JW.Treatment of the anaemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158–63.CrossRefGoogle ScholarPubMed
11Marcus, DL, Freedman, ML.Clinical disorders of iron metabolism in the elderly. Clinics Geriatr Med 1985; 1: 729–45.CrossRefGoogle ScholarPubMed
12Jensen, BM, Sando, SH, Grandjaen, P, Wiggers, P, Dalhoj, J.Screening with zinc protoporphyrin for iron deficiency anemia. JAMA 1990; 36: 846–48.Google Scholar
13Bennett, JM, Catovsky, D, Daniel, M-Tet al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–99.CrossRefGoogle ScholarPubMed
14White, AD, Culligan, DJ, Hoy, TG, Jacobs, A.Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS). Br J Haematol 1992; 81: 499–502.CrossRefGoogle ScholarPubMed
15Van den Berghe, H.The 5q– syndrome. Scand J Haematol 1986; 36: 78–81.Google Scholar
16Boogaerts, MA, Nelissen, V, Roelant, C, Goossens, W.Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983; 55: 217–27.Google Scholar
17Mufti, GJ. A guide to risk assessment in the primary myelodysplastic syndrome. In: Koeffler, HP ed. Myelodysplastic syndromes, haematology/ oncology clinics of North America. Philadelphia: WB Saunders, 1992: 587–606.Google Scholar
18Armitage, JO, Dick, FR, Needleman, SW, Burns, CP.Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 1981; 65: 601–605.Google ScholarPubMed
19Huang, E, Nocka, K, Beier, DRet al. The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990; 63: 225–33.CrossRefGoogle Scholar
20Goselink, HM, Williams, DE, Fibbe, WEet al. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells. Blood (in press).Google Scholar
21Feldman, AR, Kessler, L, Myers, MH, Naughton, MD.The prevalence of cancer. Estimates based on the Connecticut Tumour Registry. N Engl J Med 1986; 315: 1394–97.CrossRefGoogle Scholar
22Giannoulis, N, Ogier, C, Hast, R.Difference between young and old patients in characteristics of leukaemic cells: older patients have cells growing excessively in vitro, with low antigenicity despite high HLA-DR antigens. Am J Hematol 1984; 16: 113–21.Google Scholar
23Liu, Yin JA, Johnson, PRE, Davies, JM, Flanagan, NG, Gorst, DW, Lewis, MJ.Mitozanthrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991; 79: 415–20.Google Scholar
24Hanslip, JI, Swansbury, GJ, Min, T, Matutes, E, Morilla, R, Catovsky, D. The significance of trilineage myelodysplasia (TMDS) in acute myeloid leukaemia (AML): a study of clinical features, immunophenotype and karyotype in 185 patients. London: International Society of Haematology, 24th Meeting, 1992: 246.Google Scholar
25Rees, JKH, Gray, RG, Swirsky, D, Hayhoe, FGJ.Principal results of the Medical Research Council's 8th acute myeloid trial. Lancet 1986; ii: 1236–41.CrossRefGoogle Scholar
26Lowenberg, B, Zittoun, R, Kerkhofs, Het al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia: a randomised phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia group. J Clin Oncol 1989; 7: 1268–74.CrossRefGoogle Scholar
27Reiffers, J, Huguet, F, Stoppa, AM, Michallet, M, Hurteloup, P.Intensive induction chemotherapy in elderly patients. Br J Haematol 1992; 82: 175–77.Google Scholar
28De Wolf, JTM, Hendriks, DW, Egger, RC, Esselink, MT, Halie, MR, Vellenga, E.Alpha-interferon for intractable pruritis in polycythaemia vera. Lancet 1991; 337: 241.Google Scholar
29Jabaily, J, Iland, H, Laszlo, Jet al. Neurological manifestations of essential thrombocythemia. Ann Intern Med 1983; 99: 513–18.Google Scholar
30Preston, FE, Emmanual, I, Winfield, D, Malia, R.Essential thrombocytaemia and peripheral gangrene. Br J Med 1974; 3:548–52.CrossRefGoogle Scholar
31Singh, AK, Wetherley-Mein, G.Microvascular occlusive lesions in primary thrombocythaemia. Br J Haematol 1977; 36: 553–64.CrossRefGoogle ScholarPubMed
32Reilly, JT.Pathogenesis of idiopathic myelofibrosis: role of growth factors. J Clin Pathol 1992; 45: 461–64.CrossRefGoogle ScholarPubMed
33Binet, JL, Auquier, A, Dighiero, Get al. A new prognostic classification of chronic lymphatic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.Google Scholar
34Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomised, controlled clinical trial. N Engl J Med 1988; 319: 902–907.CrossRefGoogle Scholar
35Petersen, BA, Pajak, TE, Cooper, MRet al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982; 66: 889–98.Google Scholar
36Newell, GR, Cabanillas, FG, Hagemeister, FJ, Butler, JJ.Incidence of lymphoma in the US classified by the Working Formulation. Cancer 1987; 59: 857–61.Google Scholar
37Rappaport, H, Winter, WJ, Hicks, EB.Follicular lymphoma. A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956; 9: 792–96.3.0.CO;2-B>CrossRefGoogle Scholar
38Stansfeld, AG, Diebold, J, Noel, Het al. Updated Kiel classification for lymphomas. Lancet 1988; i: 292–93.Google Scholar
39Vose, JM, Armitage, JO, Weisenberger, DDet al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–44.Google Scholar
40Sonneveld, P, Michials, JJ.Full dose chemotherapy in elderly patients with non-Hodgkins lymphoma: a feasibility study using mitozanthrone containing regime. Br J Cancer 1990; 62: 105–108.CrossRefGoogle Scholar
41Watkin, SW, Green, JA.Non Hodgkin's lymphoma– a four-drug regimen suitable for elderly patients with advanced disease. Acta Oncol 1990; 29: 733–37.Google Scholar
42Gams, RA, Steinberg, J, Posner, L.Mitozanthrone in malignant lymphoma. Semin Oncol 1984; 11: 47–49.Google Scholar
43Crawford, J, Eye, MK, Cohen, HJ.Evaluation of monoclonal gammopathies in the ‘well’ elderly. Am J Med 1987; 82: 39–45.Google Scholar
44Belch, A, Shelley, W, Bergsagel, Det al. A randomised trial of maintenance versus no maintenance melphalan and prednisolone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94–99.CrossRefGoogle Scholar
45Boccadoro, M, Pileri, A.Standard chemotherapy for myelomatosis: an area of great controversy. Hematol/Oncol Clinics North Am 1992; 6: 371–82.CrossRefGoogle ScholarPubMed
46Barlogie, B, Smith, L, Alexanian, R.Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–56.Google Scholar
47Alexanian, R, Dreicer, R.Chemotherapy for multiple myeloma. Cancer 1984; 53: 583–88.Google Scholar